Updates in the Use of Liquid Biopsies for Multiple Tumor Types

July 12, 2018
Wafik El-Deiry, MD, PhD, FACP

Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses updates in the use of liquid biopsies for multiple tumor types during the 2018 ASCO Annual Meeting.

Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses updates in the use of liquid biopsies for multiple tumor types during the 2018 ASCO Annual Meeting.

El-Deiry says some areas that are fairly new in the utility of liquid biopsies include more emphasis on early detection and diagnosis of disease. New issues have also been brought to light regarding clonal hematopoiesis, which can potentially give misleading results. This has led to debates in the oncology community on how to interpret results of liquid biopsies.